Cleave Biosciences, Inc.   Report issue

For profit Phase 1
Founded: Burlingame CA United States (2010)

Organization Overview

First Clinical Trial
2014
NCT02223598
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cleave Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (3)

cb-5083 (2 trials)

cb-5339 (1 trial)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3